Robotics Industry News
Brinks Gilson & Lione Elects Four Attorneys as Shareholders, Including Ann Arbor Office’s Josh Ney, Ph.D
Brinks Gilson & Lione Posted 01/09/2019
CHICAGO – Brinks Gilson & Lione, one of the largest intellectual property law firms in the United States, has elected four attorneys as shareholders. They are Virginia Wolk Marino in Chicago; Dr. Joshua E. Ney in Ann Arbor, Mich.; and Mark D. Jenkins and Amy H. Fix in Research Triangle Park, N.C
“All four of our new shareholders are highly talented, industrious and accomplished attorneys, each committed to delivering exceptional client service,” said Gustavo Siller, President of Brinks Gilson & Lione. “They’re wonderful ambassadors for the firm, and I’m proud to welcome them to the shareholder ranks.”
- Virginia Wolk Marino focuses her practice on all aspects of domestic and global brand protection, copyright and unfair competition law. Her trademark prosecution and counseling practice includes the acquisition, maintenance, licensing, enforcement and transfer of intellectual property. With experience in the pharmaceutical and life sciences sectors, she works with clients to develop and maintain their global trademark portfolios. Virginia received her J.D. from The George Washington University Law School, and her B.A. with distinction from the University of Michigan.
- Dr. Joshua Ney represents clients in the pharmaceutical, biotechnology and chemical industries in patent litigation and patent prosecution matters and counsels clients on due diligence and freedom-to-operate issues. His litigation experience includes matters in the U.S. district courts as well as inter partes review proceedings before the Patent Trial and Appeal Board. Josh represents pharmaceutical clients in matters involving new chemical entities, second medical uses, pharmaceutical formulations, synthetic processes and pharmaceutical polymorphs. In December 2018, he was named an Up and Coming Lawyer by the trade publication, Michigan Lawyers Weekly. Josh earned his J.D., cum laude, from the University of Michigan Law School, his Ph.D. from the University of Michigan and a B.A., magna cum laude, from Dartmouth College.
- Mark Jenkins assists chemical and biotechnology clients with patent prosecution, due diligence reviews, freedom-to-operate analyses, validity analyses and post-grant proceedings in the U.S. and abroad. Mark regularly advises clients in the pharmaceutical, crop-science, polymer, and personal care sectors and has developed experience working with tissue-banking companies in the emerging area of regenerative medicine. He received his J.D., cum laude, from the University of New Hampshire School of Law, an M.S. from Vanderbilt University, and a B.S., summa cum laude, from the University of Tennessee at Martin.
- Amy Fix advises clients in preparing and prosecuting both domestic and international patent applications to create strategic portfolio value and flexibility. Having in-house experience with both large and start-up companies in small-molecule drug development, she has spent over 20 years protecting pharmaceutical, agricultural, and polymer technologies. She also counsels clients on regulatory issues associated with research and development of pharmaceuticals, biologics, and medical devices and guides clients through their due diligence reviews and associated life science-based commercial transactions. She received her J.D. from Campbell University, Normal Adrian Wiggins School of Law, and earned her B.S., cum laude, from North Carolina State University.
About Brinks Gilson & Lione
Celebrating more than 100 years of intellectual property law, Brinks Gilson & Lione is one of the largest intellectual property law firms in the U.S., and helps clients around the world to protect and enforce their intellectual property rights. Our lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information can be found at www.brinksgilson.com.